

To keep the file size to a minimum, this document contains only the Abstract and Plain Language Summary for the Cochrane Review, which should be sufficient for the purpose of rating it for Relevance and Newsworthiness. If you wish to view the entire document, please return to the rating page and choose the "Additional Info" link directly under the "View Article" link. Please note the file may be quite large.

Tiotropium versus placebo for chronic obstructive pulmonary disease (Review)

Karner C, Chong J, Poole P



**THE COCHRANE
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2014, Issue 7

<http://www.thecochranelibrary.com>

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	3
BACKGROUND	5
OBJECTIVES	6
METHODS	6
RESULTS	8
Figure 1.	9
Figure 2.	12
Figure 3.	14
Figure 4.	15
Figure 5.	16
Figure 6.	17
Figure 7.	18
DISCUSSION	19
AUTHORS' CONCLUSIONS	22
ACKNOWLEDGEMENTS	22
REFERENCES	22
CHARACTERISTICS OF STUDIES	33
DATA AND ANALYSES	77
Analysis 1.1. Comparison 1 Tiotropium versus placebo, Outcome 1 Quality of life (SGRQ total score).	80
Analysis 1.2. Comparison 1 Tiotropium versus placebo, Outcome 2 Patients with ≥ 4 units improvement in quality of life (SGRQ).	81
Analysis 1.3. Comparison 1 Tiotropium versus placebo, Outcome 3 Patients with ≥ 4 units worsening in quality of life (SGRQ).	82
Analysis 1.4. Comparison 1 Tiotropium versus placebo, Outcome 4 Subgroup analysis: Quality of life ICS/ no ICS (SGRQ).	83
Analysis 1.5. Comparison 1 Tiotropium versus placebo, Outcome 5 Subgroup analysis: Quality of life LABA/ no LABA (SGRQ).	84
Analysis 1.6. Comparison 1 Tiotropium versus placebo, Outcome 6 Subgroup analysis: Quality of life (SGRQ) by disease severity.	85
Analysis 1.7. Comparison 1 Tiotropium versus placebo, Outcome 7 Quality of life (EQ-5D total score).	86
Analysis 1.8. Comparison 1 Tiotropium versus placebo, Outcome 8 Quality of life (CRQ total score).	86
Analysis 1.9. Comparison 1 Tiotropium versus placebo, Outcome 9 Patients with ≥ 1 exacerbation.	87
Analysis 1.10. Comparison 1 Tiotropium versus placebo, Outcome 10 Subgroup analysis: patients with ≥ 1 exacerbation by study duration.	88
Analysis 1.11. Comparison 1 Tiotropium versus placebo, Outcome 11 Subgroup analysis: patients with ≥ 1 exacerbations ICS/ no ICS by concomitant medication.	90
Analysis 1.12. Comparison 1 Tiotropium versus placebo, Outcome 12 Subgroup analysis: patients with ≥ 1 exacerbation by inhaler device.	91
Analysis 1.13. Comparison 1 Tiotropium versus placebo, Outcome 13 Subgroup analysis: patients with ≥ 1 exacerbation by disease severity.	93
Analysis 1.14. Comparison 1 Tiotropium versus placebo, Outcome 14 Patients with ≥ 1 exacerbation requiring hospitalisation.	94
Analysis 1.15. Comparison 1 Tiotropium versus placebo, Outcome 15 Patients with ≥ 1 hospitalisation (all-cause).	95
Analysis 1.16. Comparison 1 Tiotropium versus placebo, Outcome 16 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by study duration.	96
Analysis 1.17. Comparison 1 Tiotropium versus placebo, Outcome 17 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by inhaler device.	98

Analysis 1.18. Comparison 1 Tiotropium versus placebo, Outcome 18 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by disease severity.	99
Analysis 1.19. Comparison 1 Tiotropium versus placebo, Outcome 19 Mortality.	101
Analysis 1.20. Comparison 1 Tiotropium versus placebo, Outcome 20 Subgroup analysis: mortality by study duration.	102
Analysis 1.21. Comparison 1 Tiotropium versus placebo, Outcome 21 Subgroup analysis: mortality by inhaler device.	104
Analysis 1.22. Comparison 1 Tiotropium versus placebo, Outcome 22 Subgroup analysis: mortality LABA/ no LABA by concomitant medication.	106
Analysis 1.23. Comparison 1 Tiotropium versus placebo, Outcome 23 Subgroup analysis: mortality ICS/LABA/ no ICS/LABA by concomitant medication.	107
Analysis 1.24. Comparison 1 Tiotropium versus placebo, Outcome 24 Subgroup analysis: mortality ICS/ no ICS by concomitant medication.	108
Analysis 1.25. Comparison 1 Tiotropium versus placebo, Outcome 25 Subgroup analysis: mortality by disease severity.	109
Analysis 1.26. Comparison 1 Tiotropium versus placebo, Outcome 26 Trough FEV1.	110
Analysis 1.27. Comparison 1 Tiotropium versus placebo, Outcome 27 Patients with ≥ 1 serious adverse event (non-fatal).	111
Analysis 1.28. Comparison 1 Tiotropium versus placebo, Outcome 28 Withdrawals.	112
ADDITIONAL TABLES	113
APPENDICES	113
WHAT'S NEW	115
HISTORY	115
CONTRIBUTIONS OF AUTHORS	116
DECLARATIONS OF INTEREST	116
SOURCES OF SUPPORT	116
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	116
INDEX TERMS	116

[Intervention Review]

Tiotropium versus placebo for chronic obstructive pulmonary disease

Charlotta Karner¹, Jimmy Chong², Phillipa Poole³

¹BMJ-TAG, BMJ, London, UK. ²Tauranga Hospital, Tauranga, New Zealand. ³Department of Medicine, University of Auckland, Auckland, New Zealand

Contact address: Charlotta Karner, BMJ-TAG, BMJ, Tavistock Square, London, WC1H 9JR, UK. ckarner@bmj.com.

Editorial group: Cochrane Airways Group.

Publication status and date: Edited (conclusions changed), published in Issue 7, 2014.

Review content assessed as up-to-date: 9 February 2012.

Citation: Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2014, Issue 7. Art. No.: CD009285. DOI: 10.1002/14651858.CD009285.pub3.

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Tiotropium is an anticholinergic agent which has gained widespread acceptance as a once daily maintenance therapy for symptoms and exacerbations of stable chronic obstructive pulmonary disease (COPD). In the past few years there have been several systematic reviews of the efficacy of tiotropium, however, several new trials have compared tiotropium treatment with placebo, including those of a soft mist inhaler, making an update necessary.

Objectives

To evaluate data from randomised controlled trials (RCTs) comparing the efficacy of tiotropium and placebo in patients with COPD, upon clinically important endpoints.

Search methods

We searched the Cochrane Airways Group's Specialised Register of Trials (CAGR) and ClinicalTrials.gov up to February 2012.

Selection criteria

We included parallel group RCTs of three months or longer comparing treatment with tiotropium against placebo for patients with COPD.

Data collection and analysis

Two review authors independently assessed studies for inclusion and then extracted data on study quality and the outcome results. We contacted study authors and trial sponsors for additional information, and collected information on adverse effects from all trials. We analysed the data using Cochrane Review Manager 5, RevMan 5.2.

Main results

This review included 22 studies of good methodological quality that had enrolled 23,309 participants with COPD. The studies used similar designs, however, the duration varied from three months to four years. In 19 of the studies, 18 mcg tiotropium once daily via the Handihaler dry powder inhaler was evaluated, and in three studies, 5 or 10 mcg tiotropium once daily via the Respimat soft mist inhaler was evaluated. Compared to placebo, tiotropium treatment significantly improved the mean quality of life (mean difference (MD) -2.89; 95% confidence interval (CI) -3.35 to -2.44), increased the number of participants with a clinically significant improvement

Tiotropium versus placebo for chronic obstructive pulmonary disease (Review)

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

(odds ratio (OR) 1.52; 95% CI 1.38 to 1.68), and reduced the number of participants with a clinically significant deterioration (OR 0.65; 95% CI 0.59 to 0.72) in quality of life (measured by the St George's Respiratory Questionnaire (SGRQ)). Tiotropium treatment significantly reduced the number of participants suffering from exacerbations (OR 0.78; 95% CI 0.70 to 0.87). This corresponds to a need to treat 16 patients (95% CI 10 to 36) with tiotropium for a year in order to avoid one additional patient suffering exacerbations, based on the average placebo event rate of 44% from one-year studies. Tiotropium treatment led to fewer hospitalisations due to exacerbations (OR 0.85; 95% CI 0.72 to 1.00), but there was no statistically significant difference in all-cause hospitalisations (OR 1.00; 95% CI 0.88 to 1.13) or non-fatal serious adverse events (OR 1.03; 95% CI 0.97 to 1.10). Additionally, there was no statistically significant difference in all-cause mortality between the tiotropium and placebo groups (Peto OR 0.98; 95% CI 0.86 to 1.11). However, subgroup analysis found a significant difference between the studies using a dry powder inhaler and those with a soft mist inhaler (test for subgroup differences: $P = 0.01$). With the dry powder inhaler there were fewer deaths in the tiotropium group (Peto OR 0.92; 95% CI 0.80 to 1.05) than in the placebo group (yearly rate 2.8%), but with the soft mist inhaler there were significantly more deaths in the tiotropium group (Peto OR 1.47; 95% CI 1.04 to 2.08) than in the placebo group (yearly rate 1.8%). It is noted that the rates of patients discontinuing study treatment were uneven, with significantly fewer participants withdrawing from tiotropium treatment than from placebo treatment (OR 0.66; 95% CI 0.59 to 0.73). Participants on tiotropium had improved lung function at the end of the study compared with those on placebo (trough forced expiratory volume in one second (FEV₁) MD 118.92 mL; 95% CI 113.07 to 124.77).

Authors' conclusions

This review shows that tiotropium treatment was associated with a significant improvement in patients' quality of life and it reduced the risk of exacerbations, with a number needed to treat to benefit (NNTB) of 16 to prevent one exacerbation. Tiotropium also reduced exacerbations leading to hospitalisation but no significant difference was found for hospitalisation of any cause or mortality. Thus, tiotropium appears to be a reasonable choice for the management of patients with stable COPD, as proposed in guidelines. The trials included in this review showed a difference in the risk of mortality when compared with placebo depending on the type of tiotropium delivery device used. However, these results have not been confirmed in a recent trial when 2.5 mcg or 5 mcg of tiotropium via Respimat was used in a direct comparison to the 18 mcg Handihaler.

PLAIN LANGUAGE SUMMARY

Tiotropium for managing COPD

Chronic obstructive pulmonary disease (COPD) is a lung disease which includes the conditions, chronic bronchitis and emphysema. It is caused by smoking or inhaled dust, which leads to blockage or narrowing of the airways. The symptoms include breathlessness and a chronic cough. Tiotropium is an inhaled medication that helps widen the airways (bronchodilator) for up to 24 hours, and is used to manage persistent symptoms of COPD.

We found 22 studies including 23,309 participants, comparing the long-term effectiveness and side effects of tiotropium and placebo. Compared with placebo, tiotropium treatment led to an improvement in quality of life, fewer people had an exacerbation (worsening of COPD symptoms), or exacerbations leading to hospital admissions. The number of people that needed to be treated for a year, for one person to avoid one additional exacerbation was 16 (95% confidence interval (CI) 10 to 36). We found no statistically significant difference between the tiotropium and placebo groups in terms of the number of hospital admissions for any cause, serious adverse events or deaths during the studies. However, when we divided the data depending on whether a dry powder inhaler or a soft mist inhaler was used in the studies, these two subgroups were significantly different. With the dry powder inhaler there were fewer deaths in the tiotropium group than in the placebo group, whereas with the soft mist inhaler there were significantly more deaths in the tiotropium group than in the placebo group. Also, there was a larger number of participants that stopped study medication early in the placebo group than in the tiotropium group.

This review shows that treatment with tiotropium improves patients' quality of life, and reduces the risk of exacerbations, including exacerbations leading to hospitalisation. But tiotropium does not reduce hospitalisations for all causes or the number of deaths. Based on the evidence in this review, tiotropium appears to be a reasonable treatment choice for patients with stable COPD.

To keep the file size to a minimum, this document contains only the Abstract and Plain Language Summary for the Cochrane Review, which should be sufficient for the purpose of rating it for Relevance and Newsworthiness. If you wish to view the entire document, please return to the rating page and choose the "Additional Info" link directly under the "View Article" link. Please note the file may be quite large.